Meditell: The Startup that Arrived Too Early

There is a particular kind of failure that emerges, not out of laziness or poor execution, but when a genuinely capable team builds the right product for a market that is not yet able to receive it. Meditell, a Lagos-based health technology startup active between 2014 and 2015, is an example of this in Nigerian health tech history.

The company was founded in 2014 by Michael Osahon, Oluwatobi Adegun, and Adeyinka Amurawaiye, two of whom met at an NYSC orientation camp, with the aim of improving medication adherence among Nigerians with chronic disease. Michael had already built an SMS and voice-call system that reminded patients with chronic illnesses to take their medication; this prototype would later lead to the founding of Meditell. The logic was simple. Many people with chronic conditions do not feel the strain of their illness between episodes, which weakens the daily motivation to take medication. The solution was a seamless reminder service, initiated on the hospital's end, that sent a text detailing which drug to take and at what dose, followed three minutes later by a voice call for reinforcement. The patient needed nothing more than a phone number. No smartphone, no app download, no data plan. For Nigeria's demographic reality at that time, that was an appropriately simple design.

The startup received seed funding from LeadPath Nigeria, a Lagos-based incubator, and began approaching private hospitals across the city. What followed was a story of a structurally sound idea colliding, one by one, with every load-bearing wall of the Nigerian healthcare system.

The First Wall: Who Controlled the Money?

The hospitals were receptive, but the bulk of their patients, in many cases up to 70 per cent, were enrolled under Health Maintenance Organisations. HMOs controlled a fixed price list for every hospital service. To add a new vendor charge, a hospital would need to negotiate that addition with its HMO partners. As one of the founders described in an interview, HMOs and hospitals were not friends. They were constantly at loggerheads, each trying to get the better of the other.

This meant the hospital channel was effectively closed before Meditell fully understood it was closed. Even clinicians who saw the downstream costs of non-adherence every day had no power to authorise payment for it. Meditell needed to follow the money, and it sat with the HMOs.

The Pivot and the Second Wall

The team redirected its sales effort toward HMOs, where the conversation took an unexpected turn. An HMO executive expressed interest not in the medication reminder but in a different problem entirely: the claims process. Until this time, HMOs and hospitals processed reimbursement claims on paper. A hospital would complete a long form detailing every patient's information, every ailment, every drug administered, and every price, which was then sent to the HMO for manual line-by-line review. This was the standard in 2014, and it was all done by hand.

Meditell pivoted again, this time toward building a digital claims management system to automate what was essentially a data-entry and reconciliation problem. The concept was technically straightforward, and at least one HMO appeared genuinely motivated. The team built features in response to the HMO's requirements, deepening the product. And a deal seemed close, until… the managing director left.

The new leadership arrived, and the company’s attention shifted entirely. They shifted focus from sales to the internal technology project their predecessor had been championing, as a tech-enabled competitor began poaching their customers. Call after call, reach after reach. The responses grew less frequent. This caused the deal to collapse.

Infrastructure Was The Problem Beneath

The pivot to claims management exposed something more fundamental than a sales-cycle problem: there was no pre-existing cloud system or software connecting hospitals to HMOs and back. If that infrastructure had existed, Meditell would have simply plugged in and offered its service as a value-added layer on top of what was already working. Instead, it was trying to build the base and sell the layer at the same time.

Hospitals that needed the claims system most often did not have computers, nor was the internet reliable. An American solution had been tried before but failed due to poor UX and connectivity issues. The digital preconditions for the product to function simply did not exist across the target market at the scale required for a commercially viable deployment.

Other HMOs told the team the concept was interesting, but that they needed a standard. They could not ask their hospital network to adopt one platform while another HMO asked the same hospitals to use a different one. They asked Meditell which HMO had already done it, and the team had to explain that somebody had to go first. Nobody would.

The Incentives Were Not Sufficient

Every actor in the system was behaving rationally. Patients needed adherence support, but were not the paying customers. Hospitals wanted to reduce complications but could not absorb new vendor costs within their HMO billing structure. HMOs acknowledged the inefficiency of paper claims but were unwilling to absorb the disruption and relationship risk of mandating a new system across a hospital network that already distrusted them. Regulators had no mandate to drive digital adoption. Investors were operating on seed timelines incompatible with enterprise health sales cycles in a conservative sector.

There was no villain. It was simply a system in which no actor had sufficient incentive to absorb the cost of being first, and no regulatory, financial, or competitive force was strong enough to break the standoff.

Ruling Out Negligence

Meditell's founders were neither negligent nor naive. They discovered the hospital billing architecture through direct field sales, not through investor pitch preparation. They interviewed HMO executives, pharmacies, and hospital administrators, adjusted the product twice in response to real market feedback, and did not spend their seed capital on marketing before validating institutional demand. Qualities many better-resourced startups have lacked.

The dependence on a single executive, without building institutional commitment beneath him, was perhaps one of the most strategic errors and possibly the startup’s breaking point. A more experienced sales team might have structured the engagement differently, tying the product to a formal pilot contract rather than an informal understanding. But even with improved sales discipline, the absence of digital infrastructure in the target hospital network and of any regulatory push toward electronic claims would have posed adoption challenges that no sales strategy could overcome within an 18-month timeline.

Final Lessons

The Nigerian healthcare sector is ripe for change and full of expensive inefficiencies that should not exist. But it needs money, patience and understanding, more than any optimistic founder might expect. The opportunities that exist are genuinely hard, and their difficulty has historically discouraged sustained effort.

A decade on, some of those conditions have shifted. Newer-generation HMOs with technology mandates have entered the market. The National Health Insurance Authority Act of 2022 introduced a stronger regulatory architecture for the sector, and Nigeria's health insurance market has since grown, though formal coverage still reaches less than 20% of the population.

What Meditell attempted in 2014 is now commercially feasible in ways it was not then. Startups like mPharma, via their consumer-facing mymutti digital health platform, which allows patients to manage their prescriptions and register for their Chronic Disease Support programme, have a built-in medication reminder system, which has been reported to be effective.

This confirms that the startup did not fail because the founders were wrong about the problem, but because the sector was not yet ready, and the startup could not afford to wait.